Regeneron · 4 days ago
Sr Associate Scientist - Gene Therapy Assay Development
Wonder how qualified you are to the job?
BiopharmaBiotechnology
Insider Connection @Regeneron
Responsibilities
Learning new methods and/or technologies relevant to various projects
Planning, initiating, and completing biochemical, molecular, and immune-based assays like qPCR, ddPCR, ELISAs in a laboratory setting
Accurately documenting findings and lab records in an electronic laboratory notebook
Performing multiple assays within the same day and working on multiple projects simultaneously
Identifying and evaluating new technologies for the development of assays using new formats or techniques
Maintaining GLP compliance for all laboratory work and documentation related to assay validations in accordance with FDA regulations and company SOPs
Routinely presenting data in formal and informal meetings
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
Bachelors or Masters degree in biology or a related field with 3-6+ years of proven experience
Hands-on knowledge in PCR (quantitative PCR and digital droplet PCR) and a proven understanding of additional methodologies to assess DNA/RNA
Prior experience in gene therapies and/or bioanalytical assay platform development
Benefits
Health and wellness programs
Fitness centers
Equity awards
Annual bonuses
Paid time off
Company
Regeneron
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.
H1B Sponsorship
Regeneron has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Trends of Total Sponsorships
2023 (104)
2022 (125)
2021 (116)
2020 (122)
Funding
Current Stage
Public CompanyTotal Funding
$13.9MKey Investors
U.S. Department of Health & Human Services
2023-10-18Post Ipo Equity· $5M
2016-08-22Post Ipo Equity· $8.9M
1991-04-12IPO· nasdaq:REGN
Leadership Team
Recent News
2024-06-03
2024-06-01
2024-05-28
Company data provided by crunchbase